Nateglinide

Drug #1749

Nateglinide is an orally effective insulin secretagogue derived from D-phenylalanine.it stimulates insulin secretion by inhibiting ATP-sensitive potassium channels in pancreatic ß-cells. Nateglinide is apprivrd by FDA for the management of type II diabetes mellitus and is more effective when given preprandially.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 317.42 · Non-proprietary name: Nateglinide.

Pharmacokinetics

Distribution: Nateglinide has a plasma protein binding is 98%.

Elimination: it is metabolised via Liver, plasma half-life is 1.4hr, renal excretion is Mainly in urine.

Indications

Nateglinide is primarily indicated in conditions like Cardiopulmonary resuscitation, Type II diabetes mellitus.

Contraindications

Nateglinide is contraindicated in conditions like Pregnancy, Breast feeding.

Dosage

Nateglinide's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
60 – 120 mg	—	Every 8h	PO	Should be taken shortly before meal. This may be increased to 180mg 3 times daily.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

9 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Nateglinide is known to cause more or less tolerable side effects which are usually transient. These include Hypersensitivity reactions, Hypoglycemia, Pruritus , Rashes , Urticaria.

Warnings / Precautions

Substitute insulin during intercurrent illness (such as myocardial infarction, coma, infection and trauma) and during surgery; debilitated and malnourished patients; moderate hepatic impairment (avoid if severe).

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs

120 mg 60 mg

Drug Classification

1.18.7.1 — Insulins

Manufacturers

Manufacturers of Nateglinide in Pakistan:

Wilshire